FTSE MIB
33.324,12 -630,16 (-1,86%) Dow Jones
37.801,98 +66,87 (+0,18%) Nasdaq
15.871,03 -13,99 (-0,09%) Nikkei 225
38.471,20 -761,60 (-1,94%) Petrolio
85,56 +0,15 (+0,18%) Bitcoin EUR
58.590,89 -1.973,86 (-3,26%)
Interpace Biosciences, Inc. (IDXG)
| Chiusura precedente | 1,4700 |
| Aperto | 1,3700 |
| Denaro | 0,0000 x 800 |
| Lettera | 0,0000 x 800 |
| Min-Max giorno | 1,3700 - 1,5200 |
| Intervallo di 52 settimane | 0,6203 - 3,5400 |
| Volume | |
| Media Volume | 5.575 |
| Capitalizzazione | 6,39M |
| Beta (5 anni mensile) | 0,67 |
| Rapporto PE (ttm) | 5,84 |
| EPS (ttm) | 0,2500 |
| Prossima data utili | 10 mag 2024 - 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireInterpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year driven by additional commercial contracts and collection initiatives PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financia
- GlobeNewswire
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
Q2 Revenue of $11 million; a 49.1% increase year-over-year and 12.2% better than Q1; highest quarter in history1st Half Revenue $20.9 million; 36.1% improvement over 1st Half 2022Q2 Test volume up 15.2% year-over-year to record levels; 1st Half volume up 16.5% year-over-yearNovitas announces that LCD L39365 has been rescinded and will NOT go into effect July 17, 2023 PARSIPPANY, NJ, July 10, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today a
- GlobeNewswire
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) which establishes non-coverage for the Company’s widely used PancraGEN® test effective July 17, 2023. Commercially available in its current form since 2013, PancraGEN is a DNA-based molecular diagnostic test that
